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Introduction {#sec001}
============

Colorectal cancer (CRC) is ranked as the third most commonly diagnosed cancer type and the fourth most frequent cause of cancer-related deaths around the world\[[@pone.0163523.ref001]\]. In the United States, CRC accounts for 8% of new cancer cases and 8% of cancer deaths in men and women\[[@pone.0163523.ref002]\]. Significant progress has been achieved in the past two decades to improve the clinical outcomes of CRC, including the approval of several therapeutic agents for chemotherapy and targeted therapy \[[@pone.0163523.ref003]\]. Despite this, 24%-41% of patients die within 5 years following a surgical resection with curative intent, and 56%-78% of patients die within 2 years after palliative resection \[[@pone.0163523.ref004]\]. Therefore, it is necessary to identify novel and readily available prognostic biomarkers for risk stratification and to predict treatment efficiency in CRC.

Inflammation has been indicated to serve a pivotal role in cancer development\[[@pone.0163523.ref005]\]. Inflammatory responses can facilitate tumor progression in different stages, including initiation, proliferation, angiogenesis, invasion, and metastasis \[[@pone.0163523.ref006], [@pone.0163523.ref007]\]. In recent years, blood based inflammatory parameters including neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR), have attracted extensive attention and have been studied in a wide spectrum of diseases\[[@pone.0163523.ref008]--[@pone.0163523.ref010]\]. This is because these indexes of systemic inflammation are easy to measure and provide useful information for prognosis \[[@pone.0163523.ref011], [@pone.0163523.ref012]\]. PLR is calculated as the platelet count divided by the lymphocyte count. In the process of tumor angiogenesis, proangiogenic mediators could promote the release of platelets\[[@pone.0163523.ref013]\]. In addition, antiplatelet agents have been shown to inhibit the growth ability of cancer cells by down-regulating matrix metalloproteinase-9 \[[@pone.0163523.ref014]\]. Therefore, platelets could reflect the invasive potential of cancer cells to some extent. Lymphocytes, by contrast, are involved in cancer immune surveillance \[[@pone.0163523.ref015]\]. Lymphocytes also participate in tumor defense by inducing cytotoxic cell death and suppressing the proliferation of tumor cells as well as their maturation \[[@pone.0163523.ref005], [@pone.0163523.ref016]\]. Therefore, the index combining platelets and lymphocytes, PLR, could provide a relatively objective and reliable measurement of the protumor and antitumor effects in patients. Compared with platelets, lymphocytes have a greater involvement in systemic inflammatory responses in patients with cancer and are more easily to be influenced. Therefore, the changes in lymphocyte counts have a more profound influence on PLR. High PLR has been shown to be a potential prognostic indicator in a variety of solid tumors, such as gastric cancer\[[@pone.0163523.ref017]\], non-small-cell lung cancer\[[@pone.0163523.ref018]\], breast cancer\[[@pone.0163523.ref019]\] and hepatocellular carcinoma\[[@pone.0163523.ref020]\]. In addition, a series of studies were designed to investigate the prognostic value of PLR in colorectal cancer \[[@pone.0163523.ref021]--[@pone.0163523.ref027]\]; however, the data in these studies presented inconsistent and inconclusive results. Therefore, a comprehensive analysis combining the controversial data is required.

The aim of this study was to provide a systematic and comprehensive evaluation of the prognostic value of PLR in CRC by meta-analysis. We combined results from 13 studies and assessed the prognosis role of PLR for overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS), cancer-specific survival (CSS), and time to recurrence (TTR) in CRC.

Materials and Methods {#sec002}
=====================

Literature search {#sec003}
-----------------

This meta-analysis was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the PRISMA checklist was shown in [S1 PRISMA Checklist](#pone.0163523.s001){ref-type="supplementary-material"}. A thorough literature search was performed in the databases of PubMed, Embase, and Web of Science. The latest search was updated on March, 2016. The following terms were used: "PLR or platelet to lymphocyte ratio or platelet-lymphocyte ratio" and "colon cancer or rectal cancer or colorectal cancer or colorectal neoplasms". References from relevant articles were also examined for possible inclusions.

Selection criteria {#sec004}
------------------

The inclusion criteria were as follows: 1. the diagnosis of CRC was pathologically established; 2. the value of PLR was measured by blood based approaches prior to treatment; 3. information between PLR and clinical outcomes including OS, DFS, RFS, CSS and/or TTR was provided or sufficient data was provided for the estimation of hazard ratio (HR) and 95% confidence interval (CI); 4. a cut-off value to define high PLR was provided; 5. for overlapping studies, the most recent one was selected; 6. the study was published in English. The exclusion criteria were as follows: 1. letters, reviews, meeting abstracts, case reports or nonhuman studies; 2. insufficient data to estimate HRs and 95% CIs; 3. overlapping or duplicate studies.

Data extraction {#sec005}
---------------

Two investigators (XB,G and XS,G) independently extracted the following information from the included studies: first author, publication year, country, study period, sample size, tumor stage, tumor location, PLR cut-off value, treatment methods, and survival analysis. Regarding treatment methods, in the case that all patients received any combination of surgical resection, chemotherapy and radiotherapy treatment, the treatment method was identified as "mixed". In the event that all of the patients received surgical resection while only a number of them received chemotherapy or radiotherapy, the treatment method was labeled as "surgery". Any disagreement between the two investigators was settled by discussion.

Statistical analysis {#sec006}
--------------------

HRs and 95% CIs were selected to assess the association between PLR and prognosis in CRC. Cochran's Q test\[[@pone.0163523.ref028]\] and the Higgins I^2^ statistic\[[@pone.0163523.ref029]\] were used to estimate heterogeneity. I^2^\>50% or P~h~\<0.1 indicated significant heterogeneity. Both the random-effects model (DerSimonian Laird method)\[[@pone.0163523.ref030]\] and fixed-effects model (Mantel Haenszel method)\[[@pone.0163523.ref031]\] were employed to calculate combined HRs and 95% CIs. In the event that significant heterogeneity was found, the random-effects model was selected to explain the results, while, the fixed-effects model was used. Subgroup analysis stratified by clinical and pathological factors was performed to investigate and interpret heterogeneity between different studies. Publication bias was evaluated by Begg's funnel plot\[[@pone.0163523.ref032]\] and Egger's test\[[@pone.0163523.ref033]\]. All statistical analyses were performed using STATA V.12.0 (Stata Corp, College Station, TX). P\<0.05 was considered as statistically significant.

Results {#sec007}
=======

Literature selection and characteristics of included studies {#sec008}
------------------------------------------------------------

The initial literature search identified 210 records from the databases of PubMed, Embase, and Web of Science, and reference lists. Subsequent to an evaluation of these records, 181 records were excluded because they were reviews, irrelevant studies, meeting abstracts, duplicate records or animal studies. Therefore, 29 full-text articles were examined for eligibility. Sixteen records were further excluded after analysis of the full-text because they failed to provide key information, did not present a PLR cut-off value, had been published as a letter or were duplicate articles from the same research group. As in Baranyai's study\[[@pone.0163523.ref023]\], the investigators recruited 336 patients with CRC and 118 patients with metastatic CRC (mCRC). The CRC group and mCRC group were independent cohorts and were analyzed separately, and thus, we named the CRC cohort 'Baranyai1' and the mCRC cohort 'Baranyai2'. Finally, 13 studies (14 cohorts)\[[@pone.0163523.ref021]--[@pone.0163523.ref027], [@pone.0163523.ref034]--[@pone.0163523.ref039]\] were included in the meta-analysis. The literature selection procedures are shown in [Fig 1](#pone.0163523.g001){ref-type="fig"}. All of the included studies had a retrospective study design, and were published between 2012 and 2016. Four studies\[[@pone.0163523.ref026], [@pone.0163523.ref037]--[@pone.0163523.ref039]\] were conducted in China, three \[[@pone.0163523.ref034]--[@pone.0163523.ref036]\] were performed in Japan, two \[[@pone.0163523.ref021], [@pone.0163523.ref024]\] were carried out in UK, one study was performed in Korea \[[@pone.0163523.ref022]\], one was from Hungary \[[@pone.0163523.ref023]\], one was conducted in Austria \[[@pone.0163523.ref025]\] and one was performed in Canada \[[@pone.0163523.ref027]\]. The total sample size of the 13 studies (14 cohorts) was 8,601. The main characteristics of included studies were depicted in [Table 1](#pone.0163523.t001){ref-type="table"}.

![Flow diagram of literature selection.](pone.0163523.g001){#pone.0163523.g001}

10.1371/journal.pone.0163523.t001

###### Main characteristics of included studies.

![](pone.0163523.t001){#pone.0163523.t001g}

  Study        Year   Country   Ethnicity   Study period   No. of patients   Gender (M/F)   Tumor stage   Tumor location   Treatment   Cut-off                                         Follow-up (month)   Survival analysis
  ------------ ------ --------- ----------- -------------- ----------------- -------------- ------------- ---------------- ----------- ----------------------------------------------- ------------------- -------------------
  Carruthers   2012   UK        Caucasian   2000--2005     115               75/40          Ⅰ-Ⅲ           Rectum           Mixed       160                                             37.1                OS,DFS,TTR
  Son          2013   Korea     Asian       2005--2007     624               368/256        Ⅰ-Ⅲ           Colorectum       Surgery     300                                             42(1--66)           OS,DFS
  Baranyai1    2014   Hungary   Caucasian   2001--2011     336               180/156        Ⅰ-Ⅳ           Colorectum       Surgery     300                                             36.1                OS,DFS
  Baranyai2    2014   Hungary   Caucasian   2001--2011     118               80/38          Ⅳ             Colorectum       Surgery     300                                             36.1                OS
  Neofytou     2014   UK        Caucasian   2005--2012     140               88/52          Ⅳ             Colorectum       Mixed       150                                             33(1--103)          OS,DFS
  Szkandera    2014   Austria   Caucasian   1996--2011     372               217/155        Ⅱ-Ⅲ           Colon            Surgery     176,225[^a^](#t001fn002){ref-type="table-fn"}   68(1--190)          OS,TTR
  Ying         2014   China     Asian       2005--2010     205               144/61         Ⅰ-Ⅲ           Colorectum       Surgrey     176                                             To Dec,2013         OS,RFS,CSS
  Choi         2015   Canada    Caucasian   2004--2012     549               296/253        Ⅰ-Ⅲ           Colorectum       Surgery     295                                             NA                  OS,RFS
  Mori         2015   Japan     Asian       2007--2011     157               90/67          Ⅰ-Ⅲ           Colorectum       Surgery     150                                             20.5(0.2--62.4)     DFS
  Ozawa        2015   Japan     Asian       2000--2010     234               142/92         Ⅱ             Colorectum       Surgery     254                                             64(1--173)          OS,DFS,CSS
  Toiyama      2015   Japan     Asian       2001--2012     89                66/23          Ⅰ-Ⅲ           Rectum           Mixed       150                                             NA                  OS,RFS
  Li           2016   China     Asian       2007--2014     5,336             3,167/2,169    Ⅰ-Ⅲ           Colorectum       Surgery     219                                             55.2                OS,DFS
  Li           2016   China     Asian       2003--2012     110               58/52          Ⅳ             Colon            Mixed       162                                             0.9--122            OS
  Zou          2016   China     Asian       2006--2012     216               137/79         Ⅰ-Ⅳ           Colorectum       Surgery     246.36                                          To Jul,2013         OS

OS: overall survival; DFS: disease-free survival; TTR: time to recurrence; CSS: cancer-specific survival; RFS: recurrence-free survival; NA: not available

^a^:176 for TTR, 225 for OS.

PLR and prognosis for OS {#sec009}
------------------------

A total of 12 studies (13 cohorts)\[[@pone.0163523.ref021]--[@pone.0163523.ref027], [@pone.0163523.ref035]--[@pone.0163523.ref039]\] with 8,444 patients were used to investigate the relationship between PLR and OS in CRC. The pooled HR and 95%CI were HR = 1.81, 95%CI:1.42--2.31, p\<0.001 in the random-effects model, with heterogeneity (I^2^ = 65%, P~h~ = 0.002)([Fig 2](#pone.0163523.g002){ref-type="fig"}, [Table 2](#pone.0163523.t002){ref-type="table"}). Subgroup analysis stratified by ethnicity, sample size, tumor location, metastasis status, and treatment demonstrated that PLR had an enhanced prognostic value in Caucasian patients (HR = 1.95, 95%CI: 1.35--2.8, p\<0.001; I^2^ = 59%, P~h~ = 0.032), in small sample studies (n\<300): HR = 1.94, 95%CI: 1.57--2.4, p\<0.001 with moderate heterogeneity (I^2^ = 23.7%, Ph = 0.24) and for those with metastatic disease (HR = 1.98, 95%CI: 1.1--3.55, p = 0.022; I^2^ = 57.1%, P~h~ = 0.097). High PLR also predicted poor OS in CRC (HR = 1.94, 95%CI: 1.4--2.68, p\<0.001; I^2^ = 70.8%, P~h~ = 0.001); however, the difference was not significant in rectal cancer (HR = 1.25, 95%CI: 0.75--2.14, p = 0.404; I^2^ = 29.3%, P~h~ = 0.234).

![Forest plot of HR for the association between PLR and OS stratified by tumor location in CRC.](pone.0163523.g002){#pone.0163523.g002}

10.1371/journal.pone.0163523.t002

###### Summary of the meta-analysis results.

![](pone.0163523.t002){#pone.0163523.t002g}

  Analysis                    No. of studies   Percent (%)   References                                                                                                                                                                                           No. of patients   Random-effects model   Fixed-effects model   Heterogeneity                       
  --------------------------- ---------------- ------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------- ---------------------- --------------------- ------------------ --------- ------ ---------
  OS                                                                                                                                                                                                                                                                                                                                                                 
  Overall                     13               100           \[[@pone.0163523.ref021]--[@pone.0163523.ref027], [@pone.0163523.ref035]--[@pone.0163523.ref039]\]                                                                                                   8,444             1.81(1.42--2.31)       \<0.001               1.65(1.45--1.89)   \<0.001   61.5   0.002
  Subgroup1: ethnicity                                                                                                                                                                                                                                                                                                                                               
  Caucasian                   6                46.15         \[[@pone.0163523.ref021], [@pone.0163523.ref023]--[@pone.0163523.ref025], [@pone.0163523.ref027]\]                                                                                                   1,630             1.95(1.35--2.8)        \<0.001               2.04(1.62--2.56)   \<0.001   59     0.032
  Asian                       7                53.85         \[[@pone.0163523.ref022], [@pone.0163523.ref026], [@pone.0163523.ref035]--[@pone.0163523.ref039]\]                                                                                                   6,814             1.69(1.23--2.32)       0.001                 1.48(1.26--1.75)   \<0.001   56.9   0.03
  Subgroup2: sample size                                                                                                                                                                                                                                                                                                                                             
  \>300                       5                38.46         \[[@pone.0163523.ref022], [@pone.0163523.ref023], [@pone.0163523.ref025], [@pone.0163523.ref027], [@pone.0163523.ref037]\]                                                                           7,217             1.81(1.15--2.86)       0.011                 1.48(1.25--1.76)   \<0.001   78     0.001
  \<300                       8                61.54         \[[@pone.0163523.ref021], [@pone.0163523.ref023], [@pone.0163523.ref024], [@pone.0163523.ref026], [@pone.0163523.ref035], [@pone.0163523.ref036], [@pone.0163523.ref038], [@pone.0163523.ref039]\]   1,227             1.9(1.48--2.44)        \<0.001               1.94(1.57--2.4)    \<0.001   23.7   0.24
  Subgroup3: tumor location                                                                                                                                                                                                                                                                                                                                          
  Rectum                      2                15.38         \[[@pone.0163523.ref021], [@pone.0163523.ref036]\]                                                                                                                                                   204               1.18(0.59--2.36)       0.636                 1.25(0.75--2.14)   0.404     29.3   0.234
  Colon                       2                15.38         \[[@pone.0163523.ref025], [@pone.0163523.ref038]\]                                                                                                                                                   482               1.82(1.25--2.65)       0.002                 1.82(1.26--2.61)   0.001     6.3    0.301
  Colorectum                  9                69.24         \[[@pone.0163523.ref022]--[@pone.0163523.ref024], [@pone.0163523.ref026], [@pone.0163523.ref027], [@pone.0163523.ref035], [@pone.0163523.ref037], [@pone.0163523.ref039]\]                           7,758             1.94(1.4--2.68)        \<0.001               1.66(1.43--1.93)   \<0.001   70.8   0.001
  Subgroup4: metastasis                                                                                                                                                                                                                                                                                                                                              
  Localized                   10               76.92         \[[@pone.0163523.ref021]--[@pone.0163523.ref023], [@pone.0163523.ref025]--[@pone.0163523.ref027], [@pone.0163523.ref035]--[@pone.0163523.ref037], [@pone.0163523.ref039]\]                           8,076             1.76(1.34--2.23)       \<0.001               1.59(1.38--1.83)   \<0.001   63     0.004
  Metastatic                  3                23.08         \[[@pone.0163523.ref023], [@pone.0163523.ref024], [@pone.0163523.ref038]\]                                                                                                                           368               1.98(1.1--3.55)        0.022                 2.14(1.48--3.09)   \<0.001   57.1   0.097
  Subgroup5: treatment                                                                                                                                                                                                                                                                                                                                               
  Mixed                       4                30.77         \[[@pone.0163523.ref021], [@pone.0163523.ref024], [@pone.0163523.ref036], [@pone.0163523.ref038]\]                                                                                                   454               1.85(1.15--2.98)       0.012                 1.97(1.43--2.71)   \<0.001   50.8   0.107
  Surgery                     9                69.23         \[[@pone.0163523.ref022], [@pone.0163523.ref023], [@pone.0163523.ref025]--[@pone.0163523.ref027], [@pone.0163523.ref035], [@pone.0163523.ref037], [@pone.0163523.ref039]\]                           7,990             1.8(1.34--2.41)        \<0.001               1.59(1.38--1.84)   \<0.001   66.2   0.003
  DFS                                                                                                                                                                                                                                                                                                                                                                
  Overall                     7                100           \[[@pone.0163523.ref021]--[@pone.0163523.ref024], [@pone.0163523.ref034], [@pone.0163523.ref035], [@pone.0163523.ref037]\]                                                                           6,942             1.84(1.22--2.76)       0.003                 1.28(1.13--1.46)   \<0.001   78.3   \<0.001
  Subgroup1: ethnicity                                                                                                                                                                                                                                                                                                                                               
  Caucasian                   3                42.86         \[[@pone.0163523.ref021], [@pone.0163523.ref023], [@pone.0163523.ref024]\]                                                                                                                           591               1.93(1.12--3.34)       0.018                 1.92(1.45--2.53)   \<0.001   72.9   0.025
  Asian                       4                57.14         \[[@pone.0163523.ref022], [@pone.0163523.ref034], [@pone.0163523.ref035], [@pone.0163523.ref037]\]                                                                                                   6,351             1.78(0.97--3.26)       0.064                 1.15(0.99--1.33)   0.067     69.7   0.019
  Subgroup2: sample size                                                                                                                                                                                                                                                                                                                                             
  \>300                       3                42.86         \[[@pone.0163523.ref022], [@pone.0163523.ref023], [@pone.0163523.ref037]\]                                                                                                                           6,296             1.84(0.76--4.44)       0.177                 1.18(1.02--1.36)   0.028     88.5   \<0.001
  \<300                       4                57.14         \[[@pone.0163523.ref021], [@pone.0163523.ref024], [@pone.0163523.ref034], [@pone.0163523.ref035]\]                                                                                                   646               1.8(1.28--2.54)        0.001                 1.77(1.34--2.35)   \<0.001   24     0.267
  Subgroup3: tumor location                                                                                                                                                                                                                                                                                                                                          
  Rectum                      1                14.29         \[[@pone.0163523.ref021]\]                                                                                                                                                                           115               1.2(0.69--2.08)        0.515                 1.2(0.69--2.08)    0.515     \-     \-
  Colorectum                  6                85.71         \[[@pone.0163523.ref022]--[@pone.0163523.ref024], [@pone.0163523.ref034], [@pone.0163523.ref035], [@pone.0163523.ref037]\]                                                                           6,827             2.01(1.24--3.25)       0.005                 1.29(1.13--1.27)   \<0.001   81.8   \<0.001
  Subgroup4: treatment                                                                                                                                                                                                                                                                                                                                               
  Mixed                       2                28.57         \[[@pone.0163523.ref021], [@pone.0163523.ref024]\]                                                                                                                                                   255               1.53(1.05--2.23)       0.027                 1.55(1.12--2.15)   0.008     22.1   0.257
  Surgery                     5                71.43         \[[@pone.0163523.ref022], [@pone.0163523.ref023], [@pone.0163523.ref034], [@pone.0163523.ref035], [@pone.0163523.ref037]\]                                                                           6,687             2.11(1.11--4.01)       0.023                 1.24(1.08--1.43)   0.003     83.9   \<0.001
  RFS                                                                                                                                                                                                                                                                                                                                                                
  Overall                     3                100           \[[@pone.0163523.ref026], [@pone.0163523.ref027], [@pone.0163523.ref036]\]                                                                                                                           843               1.84(1.41--2.41)       \<0.001               1.84(1.41--2.41)   \<0.001   0      0.686
  CSS                                                                                                                                                                                                                                                                                                                                                                
  Overall                     2                100           \[[@pone.0163523.ref026], [@pone.0163523.ref035]\]                                                                                                                                                   439               1.75(0.59--5.17)       0.309                 1.3(0.87--1.96)    0.202     66.2   0.085
  TTR                                                                                                                                                                                                                                                                                                                                                                
  Overall                     2                100           \[[@pone.0163523.ref021], [@pone.0163523.ref025]\]                                                                                                                                                   487               1.21(0.62--2.36)       0.573                 1.33(0.91--1.96)   0.145     58.4   0.121

PLR and prognosis for DFS {#sec010}
-------------------------

Seven studies\[[@pone.0163523.ref021]--[@pone.0163523.ref024], [@pone.0163523.ref034], [@pone.0163523.ref035], [@pone.0163523.ref037]\] involving a total of 6,942 subjects provided the data of PLR for DFS prognosis. The overall HR and 95% CI were HR = 1.84, 95%CI:1.22--2.76, p = 0.003, although with heterogeneity (I^2^ = 78.3%, P~h~\<0.001)([Fig 3](#pone.0163523.g003){ref-type="fig"}, [Table 2](#pone.0163523.t002){ref-type="table"}). Stratified analysis suggested that elevated PLR predicted reduced DFS in Caucasian patients (HR = 1.93, 95%CI: 1.12--3.34, p = 0.018; I^2^ = 72.9%, P~h~ = 0.025); however, the result was not statistically significant for Asian patients (HR = 1.78, 95%CI: 0.97--3.26, p = 0.064; I^2^ = 69.7%, P~h~ = 0.019) ([Table 2](#pone.0163523.t002){ref-type="table"}). High PLR was also associated with poorer DFS in patients treated with surgery (HR = 2.11, 95%CI: 1.11--4.01, p = 0.023; I^2^ = 83.9%, P~h~\<0.001).

![Forest plot of HR for the association between PLR and DFS stratified by ethnicity in CRC.](pone.0163523.g003){#pone.0163523.g003}

PLR and prognosis for RFS, CSS, and TTR {#sec011}
---------------------------------------

Three studies \[[@pone.0163523.ref026], [@pone.0163523.ref027], [@pone.0163523.ref036]\] involving a total of 843 patients included data for PLR in RFS. The combined HR and 95%CI were HR = 1.84, 95%CI:1.41--2.41, p\<0.001, with fine homogeneity (I^2^ = 0,P~h~ = 0.686). Pooled data from two studies \[[@pone.0163523.ref026], [@pone.0163523.ref035]\] showed that PLR had no statistically significant association with poor CSS in the random-effects model or in the fixed effects model ([Table 2](#pone.0163523.t002){ref-type="table"}). High PLR was also not able to predict poor TTR statistically, according to the pooled HRs and 95% CIs from two articles \[[@pone.0163523.ref021], [@pone.0163523.ref025]\].

Publication bias {#sec012}
----------------

Begg's test and Egger's test were employed to examine the publication bias in the meta-analysis. As shown in [Table 3](#pone.0163523.t003){ref-type="table"} and [Fig 4](#pone.0163523.g004){ref-type="fig"}, the results indicated that there was no significant publication bias present for OS, DFS, RFS, CSS and TTR analyses.

![Publication bias assessed by Begg's test and Egger's test.\
(A) Begg's test for OS; (B) Egger's test for OS; (C) Begg's test for DFS; (D) Egger's test for DFS; (E) Begg's test for RFS; (F) Egger's test for RFS.](pone.0163523.g004){#pone.0163523.g004}

10.1371/journal.pone.0163523.t003

###### Publication bias examined by Begg's test and Egger's test in meta-analysis.

![](pone.0163523.t003){#pone.0163523.t003g}

  Variables   No. of studies   Begg's p   Egger's p
  ----------- ---------------- ---------- -----------
  OS          13               0.36       0.3
  DFS         7                0.881      0.064
  RFS         3                0.291      0.319
  CSS         2                1          \-
  TTR         2                1          \-

Discussion {#sec013}
==========

In recent years, a series of studies have investigated prognostic role of PLR for CRC, selecting different events, including OS, DFS, RFS, CSS, and TTR as the end-point events. However, these studies have reported conflicting results. While a number of studies\[[@pone.0163523.ref024], [@pone.0163523.ref026], [@pone.0163523.ref038]\] suggested PLR to be an effective prognostic biomarker for CRC, other studies\[[@pone.0163523.ref021], [@pone.0163523.ref022], [@pone.0163523.ref025], [@pone.0163523.ref036]\] reported negative results with respect to the prognostication for PLR. In the present study, by using the meta-analysis analytic approach, we demonstrated that PLR predicted poor OS in CRC, especially in Caucasian patients, for metastatic disease and for CRC; however, it was not able to predict poor OS for rectal cancer. Moreover, a high PLR was correlated with shorter DFS in the overall analysis and had a more significant prognostic value in patients who had received surgery. Furthermore, PLR was also associated with poor RFS, without heterogeneity. However, there was no association between PLR and CSS and TTR in CRC. To the best of our knowledge, this is the first meta-analysis comprehensively exploring the prognostic value of PLR in CRC.

Growing evidence has shown that there is an association between inflammation and tumorigenesis \[[@pone.0163523.ref005], [@pone.0163523.ref016]\]. Recently, tumor-promoting inflammation was established as an emerging hallmark of cancer \[[@pone.0163523.ref007]\]. Persistence of the inflammatory responses in the tumor microenvironment results in the proliferation of tumor cells, in addition to their metastasis and angiogenesis. Markers of systemic inflammation such as NLR, PLR and C-reactive protein can provide implications for prognosis in CRC \[[@pone.0163523.ref040], [@pone.0163523.ref041]\]. By contrast, prior studies have demonstrated that platelets are involved in the process of tumor angiogenesis \[[@pone.0163523.ref042]\]. Thrombocytosis is a frequent phenomenon in malignant tumors. A recent study showed that platelet-derived signals were required to guide tumor cells to construct "early metastatic niches"\[[@pone.0163523.ref043]\]. Furthermore, lymphocytes exert an indispensable role in the antitumor activity of the host by inducing tumor cell apoptosis and by inhibiting tumor metastasis \[[@pone.0163523.ref044]\]. Moreover, they are able to recognize tumor antigens and exert effects in antitumor responses through mediating antibody-dependent cytotoxicity. Previous studies have reported that an elevation in platelet count is correlated with poor prognosis in colorectal cancer \[[@pone.0163523.ref045], [@pone.0163523.ref046]\]. Current evidence also shows that low tumor-infiltrating lymphocytes are significantly associated with lower 5-year OS and DFS rates in CRC\[[@pone.0163523.ref047]\]. Based on the biological rationality, the combination of platelets and lymphocytes could be more extensively altered in CRC patients than each one of them. Furthermore, when platelet counts increased and/or lymphocyte counts decreased, the ratio altered more significantly. Moreover, PLR, as a value that combines the platelet and lymphocyte counts, is a more stable indicator of the antitumor status of patients with cancer. In addition, PLR is not difficult to test and involves no added costs, making it suitable to apply in routine clinical settings. Therefore, PLR is a useful and valuable prognostic index.

PLR has been widely explored as a prognostic indicator in various types of cancers. Several meta-analyses have shown that PLR is associated with poor prognosis in patients with non-small-cell lung cancer \[[@pone.0163523.ref048]\], which was in accordance with our study. Previous studies have also investigated PLR for its predictive role in various solid tumors using meta-analysis \[[@pone.0163523.ref011], [@pone.0163523.ref049], [@pone.0163523.ref050]\]. These studies showed that PLR predicted poor prognosis in CRC, in addition to a variety of other tumors. However, the patients with CRC included in the aforementioned studies were limited and subgroup analysis for CRC was not conducted \[[@pone.0163523.ref011], [@pone.0163523.ref049], [@pone.0163523.ref050]\]. In the present study, we collected data from 13 studies involving a total of 8,601 patients and combined HRs and 95% CIs in both the random-effects model and fixed-effects model. Furthermore, various end-points for cancer patients including OS, DFS, RFS, CSS and TTR were analyzed in our study. Therefore, our meta-analysis involving patients with CRC is more comprehensive. Interestingly, in the present meta-analysis, we found that PLR was a significant prognostic marker for OS in CRC and colon cancer, but not in rectal cancer. This phenomenon may be due to the fact that different genetic features exist during colon and rectal carcinogenesis \[[@pone.0163523.ref051]\], and TP53 pathway is activated more frequently in rectal cancer than colon cancer. The activation of platelet-derived growth factor receptor alpha pathway is accompanied by the suppression of p53\[[@pone.0163523.ref052]--[@pone.0163523.ref054]\], which implies that the elevation of platelet counts may not be significant in rectal cancer carcinogenesis and could even be a protective factor in rectal cancer. Therefore, the increased PLR value was not found to be associated with OS in patients with rectal cancer, as suggested by our results.

Our study did however involve several limitations. Firstly, significant heterogeneity was observed among the included studies. Although we selected primary studies employing uniform inclusion and exclusion criteria, heterogeneity still existed between them. The heterogeneity was possibly due to the various patient ethnicities, different tumor stages, and various treatment methods used in the primary studies. Secondly, publication bias is inevitable in studies; articles with positive results are likely to be published, articles with negative results may not be published. Thus, the combined HR may have been overestimated. Thirdly, the primary studies that reported RFS, CSS, and TTR analysis were limited, so the results concerning RFS, CSS, and TTR should be treated with caution. Therefore, further well-designed and large-scale cohort studies are warranted to confirm the prognostic role of PLR in CRC.

In conclusion, our meta-analysis showed that high PLR was an effective and significant biomarker for poor OS, DFS, and RFS in patients with CRC, however; it did not demonstrate an association with CSS or TTR. Considering the limitations in our study, well-designed, large cohort studies are required to verify our results.
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